Pure Global AI
NCT06001684Not yet recruiting

Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors

A Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBR854 Cell Injection in Patients With Unresectable Locally Advanced Or Metastatic Solid Tumors
Imbioray (Hangzhou) Biomedicine Co., Ltd.Phase 1ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Solid Tumors
Drug/Device/Intervention
IBR854 Cell Injection
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Timeline & enrollment
Phase
Phase 1
Start date
Sep 01, 2023
End date
Dec 30, 2024
Enrollment
18 participants
Primary outcome

Incidence of dose limiting toxicity (DLTs),The incidence and severity of adverse events (AEs)

Summary

This study is an open-label, phase I study to evaluate the safety, tolerability,
 pharmacokinetics (PK), and preliminary efficacy of IBR854 cell injection in patients with
 unresectable, locally advanced, or metastatic solid tumors.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm of other connective and soft tissueCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Parametrium
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06001684
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06001684 through Pure Global AI's free database. This Phase 1 trial is sponsored by Imbioray (Hangzhou) Biomedicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Solid Tumors. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.